Timothy M Kuzel - JoVE Visualize

Showing results (81-90 of 119) with videos related to

Pageof 12

Sort By:

Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014

Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinomaElaine T Lam, Michael K K Wong, Neeraj Agarwal, et al.

Leukemia & Lymphoma|June 9, 2011

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.

Elife|February 3, 2022

Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic woundRuchi Roy, Janet Zayas, Sunil K Singh, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|April 23, 2008

NCCN Task Force Report: Oral chemotherapySaul N Weingart, Elizabeth Brown, Peter B Bach, et al.

The Journal of Clinical Investigation|December 5, 2018

Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progressionBing Song, Su-Hong Park, Jonathan C Zhao, et al.

Cancer|October 11, 2018

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.

Clinical Genitourinary Cancer|July 16, 2023

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.

British Journal of Haematology|October 24, 2006

Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett, Andrew M Evens, Leslie A Andritsos, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.

Cancer|March 24, 2017

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)Kevin Kalinsky, Sandra Lee, Krista M Rubin, et al.

Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:

Pageof 12

Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014

Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinomaElaine T Lam, Michael K K Wong, Neeraj Agarwal, et al.

Leukemia & Lymphoma|June 9, 2011

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.

Elife|February 3, 2022

Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic woundRuchi Roy, Janet Zayas, Sunil K Singh, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|April 23, 2008

NCCN Task Force Report: Oral chemotherapySaul N Weingart, Elizabeth Brown, Peter B Bach, et al.

The Journal of Clinical Investigation|December 5, 2018

Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progressionBing Song, Su-Hong Park, Jonathan C Zhao, et al.

Cancer|October 11, 2018

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.

Clinical Genitourinary Cancer|July 16, 2023

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.

British Journal of Haematology|October 24, 2006

Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett, Andrew M Evens, Leslie A Andritsos, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.

Cancer|March 24, 2017

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)Kevin Kalinsky, Sandra Lee, Krista M Rubin, et al.

Pageof 12